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| INTRODUC TI ON
found anaplastic lymphoma kinase (ALK) rearrangements in the specimens of patients with non-small cell lung cancer (NSCLC). 1 ALK-positive (ALK [+]) NSCLC accounts for only 3%-4% of all NSCLC cases. 2 Crizotinib is the first ALK tyrosine inhibitor (ALK-TKI) to undergo clinical development. 3 In the PROFILE 1007 and 1014 trials, which are randomized phase III studies comparing crizotinib and the standard first-line and second-line cytotoxic chemotherapies for ALK (+) NSCLC, patients who received crizotinib had significantly better progression-free survival (PFS) than those who received chemotherapy; thus, crizotinib became a standard treatment for ALK (+) NSCLC. 4, 5 Several second-generation and third-generation ALK-TKI have also been developed, including alectinib, ceritinib, brigatinib and lorlatinib. At present, among these ALK-TKI, four have been approved and are available in clinical practice in Japan, and five ALK-TKI are available in the USA and the EU.
Alectinib is a second-generation ALK-TKI, which has shown antitumor activity against ALK (+) NSCLC in patients previously treated with crizotinib. 6 In addition, J-ALEX and ALEX, which are phase III studies, have shown that alectinib significantly improved PFS compared with crizotinib and had a better toxicity profile. 7, 8 Therefore, alectinib is commonly used as a first-line treatment for ALK (+) NSCLC. Ceritinib is another second-generation ALK-TKI.  which is a phase III study, has shown that ceritinib significantly improved PFS compared with chemotherapy in patients with ALK (+) NSCLC who previously received chemotherapy and crizotinib. 9 In addition, as a first-line treatment for ALK (+) NSCLC, ceritinib significantly improved PFS compared with platinum doublet chemotherapy. 10 In September 2018, the use of lorlatinib, a third-generation ALK-TKI, which had better potency to secondary resistance mutation than that of prior generation ALK-TKI in a preclinical model, 11 was approved for the treatment of patients whose disease has progressed after crizotinib failure or those who had been treated with another ALK-TKI based on the promising results of a phase I/II trial investigating the efficacy of such drugs in patients with ALK (+) lung cancer. 12, 13 Due to these developments, several ALK-TKI are used sequentially in clinical practice at present. 14 However, disease progression due to acquired resistance inevitably occurs after several years, resulting in a major problem in clinical practice.
Recently, several mechanisms of acquired resistance to ALK-TKI have been reported. Secondary mutations in the tyrosine kinase domain of ALK are among the major resistance mechanisms.
Moreover, bypass pathway activation, such as epidermal growth factor receptor (EGFR), Met, KRAS, ALK amplification, cKIT amplification with SCF upregulation, overexpression of P-glycoprotein (P-gp) and SCLC transformation, has been identified as another resistance mechanism. [15] [16] [17] [18] [19] [20] [21] [22] [23] In contrast with T790M mutation of EGFR, which accounts for 50% of all resistance mechanisms of first-and second-generation EGFR-TKI, different mutations occurred during ALK-TKI treatment.
First-, second-and third-generation ALK-TKI have different potencies for inhibiting secondary mutations, and they can potentially treat resistance to some secondary mutations associated with the use of other ALK-TKI. 22 Therefore, the investigation of resistance mechanisms is extremely important in choosing the appropriate ALK-TKI, and the sequential use of ALK-TKI based on resistance mechanism in patients with ALK (+) lung cancer may result in better treatment outcomes.
In this study, we analyzed resistance mechanisms through serial tumor biopsy in Japanese patients during sequential treatment with ALK-TKI and revealed the sequential transition of resistance mechanisms, particularly those associated with the use of first-line alectinib.
| MATERIAL S AND ME THODS

| Patients and tissue sampling
We collected 112 tumor biopsy specimens or cavity fluid containing cancer cells from 32 ALK (+) patients during treatment. Of the 32 patients, 25 received more than two ALK-TKI. Moreover, 23 patients 
| Analysis of resistant mechanisms
| Primers for EML4-ALK PCR amplification
| Sequencing primers
| Statistical analysis
Between-group comparisons were performed using the χ 2 test.
Time-to-event endpoints (time-to-treatment failure [TTF] and overall survival) were estimated using the Kaplan-Meier method and the Graph Pad Prism 7 software, and significant differences were identified using the log-rank test. Other data, including clinical background information, were statistically analyzed using the JMP software version 14.2 (SAS Institute). A P value <0.05 was considered statistically significant and a P value <0.10 moderately significant.
The study protocol was approved by the institutional review board of the Japanese Foundation for Cancer Research (JFCR), and written informed consent was obtained from all patients. The clinical information of each patient obtained from the medical records was reviewed.
| RE SULTS
| Baseline characteristics of the patients and treatment
Thirty-two patients with ALK (+) lung cancer who received at least one ALK-TKI at the Cancer Institute Hospital of JFCR from May 2011 to September 2018 were included. The characteristics of the patients are shown in Table 1 and are similar to those reported previously. 7 The median age at diagnosis of lung cancer was 47 years, and a female predominance was observed. In terms of histological type, the patients presented with adenocarcinoma. Of 32 patients, 
| Analysis of resistance mechanism to anaplastic lymphoma kinase-tyrosine kinase inhibitors
Among the 112 tumor biopsy specimens used in 37 re-biopsy attempts, 18 specimens presented with secondary mutations in the tyrosine kinase domain of ALK, and four ALK independent resistance mechanisms (one EGFR activation, two P-gp overexpressed cases and one MET amplification) were identified in 4 specimens.
In the remaining 15 samples, resistance mechanisms could not be identified (Table S1 ).
Resistance mechanisms to each ALK-TKI are presented in Figure 2 and Table S1 . Mutations in the ALK kinase domain were considered the major drivers of resistance to ALK-TKI in our cohort: 8 (−66.7%) of 12, 7 (47%) of 15, 2 (−28.5%) of 7 and 1 (33%) of 3 specimens collected after crizotinib, alectinib, ceritinib and lorlatinib failure, respectively. The detailed resistance mechanisms were similar to those of previous reports. In crizotinib-resistant specimens, G1202R, G1269A, I1171T, L11196M, C1156Y and F1245V, as well as one EGFR activation working as the bypass pathway, were the resistance mechanisms based on the cell line established using resistant specimens ( Figure S1 ).
The frequency of secondary mutations in crizotinib resistance patients seems to be higher than that reported in the USA. 22 In alectinib-resistant specimens, G1202R and I1171N mutations were detected in the ALK, which accounted for approximately half of all alectinib-resistant cases. Meanwhile, the mechanisms in other specimens were not identified. In 2 of 7 ceritinib-resistant specimens, the following ALK secondary mutations were found: G1202R, F1174V and G1202R, and L1196M (with P-gp overexpression). However, resistance mechanisms to ceritinib in our cohort were more complicated than expected. F1174V harboring cells and G1202R mutated cells coexisted independently in 1 pleural fluid specimen. The overexpression of P-gp, a drug efflux transporter protein, was identified in 2 ceritinib refractory specimens but not in pre-treatment samples by immunohistochemistry and immunoblotting analysis as described in our previous paper. 23 Of note, 1 of these specimens had P-gp overexpression concurrent with L1196M mutation after sequential treatment with crizotinib, alectinib and ceritinib. MET gene amplification, which is well-known as EGFR-TKI resistance, a cause of bypass pathway activation-mediated resistance to alectinib or ceritinib, was identified in 1 specimen. L1196M + G1202R, a compound mutation, was also a resistance mechanism to lorlatinib in patients with L1196M who previously experienced relapse while on crizotinib treatment. 25
| Efficacy of the sequential administration of anaplastic lymphoma kinase-tyrosine kinase inhibitors
In this study, to assess the advantage of sequential ALK-TKI ther- the TTF of another group whose resistance mechanism was not identified via re-biopsy may be similar to that of the on-target group (median: 13.5 months, Figure 3C ).
In our clinical experience, we encountered a patient who received alectinib after acquiring resistance to crizotinib via F1245V mutation ( Figure 4A ) and another patient with rapid disease progression who died while on alectinib treatment, which was admin- 
| D ISCUSS I ON
Treatment for ALK (+) lung cancer has been changing since the introduction of ALK-TKI, such as crizotinib, alectinib, ceritinib and lorlatinib. A new class of ALK-TKI, which is used as front-line treatment, has improved PFS, and its sequential administration after relapse with prior ALK-TKI is beneficial. In parallel with the development of these ALK-TKI, several resistance mechanisms have been found.
One of the major resistance mechanisms of ALK-TKI is secondary mutation in the kinase domain. Sensitivity of ALK-TKI is different in each secondary mutation, as previously reported in a preclinical model by Gainor et al. 22 The approval of these ALK-TKI has changed clinical practice. That is, patients with ALK (+) lung cancer are generally treated with several ALK-TKI; this has raised some questions regarding how to accurately administer ALK-TKI in terms of resistance mechanisms.
In this study, several points focusing on resistance mechanisms associated with ALK-TKI treatment were presented via serial rebiopsies after treatment failure in clinical practice. First, the present study was the first to report on resistance mechanisms against alectinib in Japan with a measurable number of participants.
Second, secondary mutation may be observed more frequently in patients with crizotinib resistance in our cohort compared to previous reports, which may be due to the relatively higher plasma concentrations of crizotinib among Japanese ALK (+) patients than among Caucasian patients, as indicated by Fujiwara et al 26 for minutely examining resistance mechanisms using re-biopsy specimens will affect the possibility that treatment with the sequential administration of ALK-TKI would be more beneficial for patients.
Cell-free plasma DNA analysis can make significant progress in this field.
The investigation of patients with unidentified mechanisms, as shown in Figure 3C , is another important issue because an optimal to ALK-TKI may depend on the variant type of ALK fusion. 29 The G1202R, a highly refractory resistance mutation, is more likely to emerge from variant 3 than from variant 1. 29 In future studies, whether the development of resistance mechanisms in view of temporary transition is observed according to variant type must be confirmed. Fourth, in relation to ALK-TKI resistance mediated by bypass pathway activation, such as EGFR activation or MET gene amplification, a strategy that can treat resistance has not been established in clinical practice. Thus, a therapeutic strategy that can overcome such resistance must be investigated.
In this study, the analysis of resistance mechanisms using re-biopsy specimens obtained from patients with ALK (+) lung cancer was performed, and results revealed that proper utilization of multiple ALK-TKI has become an important issue following the introduction of several ALK-TKI. In clinical practice, the precise sequential use of ALK-TKI (sometimes non-ALK-TKI) based on resistance mechanisms in patients with ALK (+) lung cancer has better treatment outcomes.
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